ArticleNeurology2024
Association of Plasma Brain-Derived Tau With Functional Outcome After Ischemic Stroke.
Open access · hybridAbstract read
In one paragraph
Article in Neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 16 citations in OpenAlex.
- A roadmap towards clinical use of molecular biomarkers in acute ischaemic stroke.Nature reviews. Neurology · 2026Review
- Plasma Profile of Brain-Derived Tau After Ischemic Stroke.European journal of neurology · 2026Observational
- Atypical involvement of Alzheimer's tau proteins in diseases beyond tauopathies.Life medicine · 2026Review
- Predicting post-stroke functional outcome using explainable machine learning and integrated data.Scientific reports · 2026Article
- Blood-Based Analysis of Different Tau Variants in Patients With Multiple Traumatic Injuries.JAMA network open · 2026Article
- Recent advances in stroke biomarkers - implications for prognosis and treatment.Current opinion in neurology · 2026Review
- Elevated acute-phase plasma levels of S100A12 [EN-RAGE] are associated with vascular recurrence after ischemic stroke.European stroke journal · 2026Article
- Epitope placement tunes CSF tau biomarkers: Comparison of P-tau217 and BD-tau designs.Molecular neurodegeneration advances · 2026Article
- The association of high-sensitivity C-reactive protein-triglyceride glucose index with functional outcome in elderly patients with acute ischemic stroke undergoing intravenous thrombolysis.Frontiers in neurology · 2026Observational
- Lower baseline serum neuronal-specific enolase levels predict better rate of recovery of functional walking ability in post-acute stroke patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Tau protein: Physiological functions and multifaceted roles in neurodegenerative and psychiatric disorders.Genomic psychiatry : advancing science from genes to society · 2025Article
- The use of brain-specific biomarkers in urine for prediction of neurological outcome and extent of tissue damage following stroke.Scientific reports · 2025Article
- Plasma Profiles of Neuroglial Injury Biomarkers after Ischemic Stroke.Translational stroke research · 2025Observational
- Brain-Derived Tau as an Outcome Marker in Guillain-Barré Syndrome: A Retrospective Cohort Study.European journal of neurology · 2025Article
- Plasma brain-derived tau correlates with cerebral infarct volume.Journal of internal medicine · 2025Article
- Perspective: Use of protein S100B as a quality assurance marker for endovascular therapy in acute ischemic stroke.Frontiers in neurology · 2025Article
- Neuronal plasma biomarkers in acute ischemic stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2025Article
- The plasma p-tau217/BD-tau ratio improves biomarker short-term variability in memory clinic patients.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Tara M StanneFrom the Department of Laboratory Medicine (T.M.S., C.B., C.J.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Department of Clinical Genetics and Genomics (T.M.S., C.J.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (F.G.-O., T.K., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (F.G.-O., K.B.); Department of Research, Development, Education and Innovation (C.B.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg; Department of Neurology (K.J.), Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; and Department of Psychiatry (T.K.), University of Pittsburgh.
Fernando Gonzalez-OrtizFrom the Department of Laboratory Medicine (T.M.S., C.B., C.J.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Department of Clinical Genetics and Genomics (T.M.S., C.J.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (F.G.-O., T.K., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (F.G.-O., K.B.); Department of Research, Development, Education and Innovation (C.B.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg; Department of Neurology (K.J.), Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; and Department of Psychiatry (T.K.), University of Pittsburgh.ORCID 0000-0001-7897-9456
Cecilia BrännmarkFrom the Department of Laboratory Medicine (T.M.S., C.B., C.J.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Department of Clinical Genetics and Genomics (T.M.S., C.J.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (F.G.-O., T.K., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (F.G.-O., K.B.); Department of Research, Development, Education and Innovation (C.B.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg; Department of Neurology (K.J.), Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; and Department of Psychiatry (T.K.), University of Pittsburgh.
Katarina JoodFrom the Department of Laboratory Medicine (T.M.S., C.B., C.J.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Department of Clinical Genetics and Genomics (T.M.S., C.J.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (F.G.-O., T.K., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (F.G.-O., K.B.); Department of Research, Development, Education and Innovation (C.B.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg; Department of Neurology (K.J.), Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; and Department of Psychiatry (T.K.), University of Pittsburgh.
Thomas KarikariFrom the Department of Laboratory Medicine (T.M.S., C.B., C.J.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Department of Clinical Genetics and Genomics (T.M.S., C.J.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (F.G.-O., T.K., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (F.G.-O., K.B.); Department of Research, Development, Education and Innovation (C.B.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg; Department of Neurology (K.J.), Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; and Department of Psychiatry (T.K.), University of Pittsburgh.
Kaj BlennowFrom the Department of Laboratory Medicine (T.M.S., C.B., C.J.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Department of Clinical Genetics and Genomics (T.M.S., C.J.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (F.G.-O., T.K., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (F.G.-O., K.B.); Department of Research, Development, Education and Innovation (C.B.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg; Department of Neurology (K.J.), Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; and Department of Psychiatry (T.K.), University of Pittsburgh.ORCID 0000-0002-1890-4193
Christina JernFrom the Department of Laboratory Medicine (T.M.S., C.B., C.J.), Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg; Department of Clinical Genetics and Genomics (T.M.S., C.J.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Psychiatry and Neurochemistry (F.G.-O., T.K., K.B.), Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg; Clinical Neurochemistry Laboratory (F.G.-O., K.B.); Department of Research, Development, Education and Innovation (C.B.), Region Västra Götaland, Sahlgrenska University Hospital; Department of Clinical Neuroscience (K.J.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy, University of Gothenburg; Department of Neurology (K.J.), Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden; and Department of Psychiatry (T.K.), University of Pittsburgh.ORCID 0000-0002-7531-2354
University of Pittsburgh · US
Funding
Plasma brain-derived tau: a novel Alzheimer’s disease-type neurodegeneration biomarker with potential to complete the AT(N) scheme in bloodR01AG083874 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Thomas K Karikari · 2023 to 2026
$14.5MNIA NIH HHS R01 AG083874
Abstract
objectivesTo investigate whether circulating acute-phase brain-derived tau (BD-tau) is associated with functional outcome after ischemic stroke.
methodsPlasma tau was measured by a novel assay that selectively quantifies BD-tau in the
resultsThis study included 454 and 364 cases from the DISCUSSION: BD-tau is a promising blood-based biomarker of ischemic stroke outcomes, and future studies in larger cohorts are warranted.
Indexed as
Brain IschemiaIschemic StrokeStrokeAdultAgedBrainHumansMiddle AgedRisk Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.